Search research articles
Contact Us
Filters
Showing results (101-110 of 293) with videos related to
Page
of 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter
Chau T Dang, Anthony F Yu, Lee W Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
Shanu Modi, Katherine S Panageas, Elaine T Duck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine
Francesca Orlandi, Franco M Venanzi, Antonio Concetti, et al.
Blood Cancer Journal
|
November 29, 2023
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
Anish K Simhal, Kylee H Maclachlan, Rena Elkin, et al.
Breast Cancer Research and Treatment
|
October 8, 2017
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
David B Page, Hannah Wen, Edi Brogi, et al.
The Oncologist
|
January 4, 2019
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up
Rui Wang, Lillian M Smyth, Neil Iyengar, et al.
Archives of Pathology & Laboratory Medicine
|
October 25, 2019
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With <i>HER2</i>/CEP17 Ratio <2.0 and Average <i>HER2</i> Copy Number ≥4.0 and <6.0
Raza S Hoda, Edi Brogi, Jin Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up
Lee K Tan, Dilip Giri, Amanda J Hummer, et al.
Biorxiv : the Preprint Server for Biology
|
October 10, 2024
High WEE1 expression is independently linked to poor survival in multiple myeloma
Anish K Simhal, Ross Firestone, Jung Hun Oh, et al.
Cell Reports
|
September 15, 2015
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors
Yasuhiro Nagai, Hiromichi Tsuchiya, E Aaron Runkle, et al.
Page
of 30
Search research articles
Search
Showing results (101-110 of 293) with videos related to
Sort By:
Page
of 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter
Chau T Dang, Anthony F Yu, Lee W Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
Shanu Modi, Katherine S Panageas, Elaine T Duck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine
Francesca Orlandi, Franco M Venanzi, Antonio Concetti, et al.
Blood Cancer Journal
|
November 29, 2023
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
Anish K Simhal, Kylee H Maclachlan, Rena Elkin, et al.
Breast Cancer Research and Treatment
|
October 8, 2017
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
David B Page, Hannah Wen, Edi Brogi, et al.
The Oncologist
|
January 4, 2019
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up
Rui Wang, Lillian M Smyth, Neil Iyengar, et al.
Archives of Pathology & Laboratory Medicine
|
October 25, 2019
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With <i>HER2</i>/CEP17 Ratio <2.0 and Average <i>HER2</i> Copy Number ≥4.0 and <6.0
Raza S Hoda, Edi Brogi, Jin Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up
Lee K Tan, Dilip Giri, Amanda J Hummer, et al.
Biorxiv : the Preprint Server for Biology
|
October 10, 2024
High WEE1 expression is independently linked to poor survival in multiple myeloma
Anish K Simhal, Ross Firestone, Jung Hun Oh, et al.
Cell Reports
|
September 15, 2015
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors
Yasuhiro Nagai, Hiromichi Tsuchiya, E Aaron Runkle, et al.
Page
of 30